Isis Pharmaceuticals has secured a collaboration deal with GlaxoSmithKline which will see the latter pay $35 million in upfront cash and additional milestones in return for an option to license up to six anti-RNA therapeutic compounds at Phase II proof of concept. The deal covers rare and infectious diseases, and the targets will be contributed by GSK.
GSK to work with antisense firm Isis on rare and infectious diseases
Isis Pharmaceuticals has secured a collaboration deal with GlaxoSmithKline which will see the latter pay $35 million in upfront cash and additional milestones in return for an option to license up to six anti-RNA therapeutic compounds at Phase II proof of concept. The deal covers rare and infectious diseases, and the targets will be contributed by GSK.
More from Anti-infective
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
• By
Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.
• By
The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.
• By
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.
More from Therapeutic Category
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.